PPARG and hepatocellular carcinoma: Yet, in hepatocellular carcinoma (HCC) in vitro and in vivo models, the use of RGZ in combination with either AKT pharmacological inhibitors or AKT siRNA significantly enhanced PPAR-γ agonist-mediated inhibition of cell proliferation, stem cell-like properties, and tumor growth (153).